Nanodoses of melatonin induces apoptosis on human breast cancer cells co-cultured with colostrum cells

doi:10.33263/briac95.416423

Cited by 13 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown a relationship between the concentration of endogenous melatonin and the risk of breast cancer in humans. Specifically, research has suggested that melatonin [17,28] and its receptors have oncostatic properties in breast cancer models [29,30]. In this study, the melatonin levels showed concentrations similar to other works in the literature [12,31].…”

Section: Discussionsupporting

confidence: 87%

Polarization of Melatonin-Modulated Colostrum Macrophages in the Presence of Breast Tumor Cell Lines

Silva

França

Queiroz

et al. 2023

IJMS

View full text Add to dashboard Cite

Human colostrum and milk contain diverse cells and soluble components that have the potential to act against tumors. In breast cancer, macrophages play a significant role in immune infiltration and contribute to the progression and spread of tumors. However, studies suggest that these cells can be reprogrammed to act as an antitumor immune response. This study aimed to evaluate the levels of melatonin and its receptors, MT1 (melatonin receptor 1) and MT2 (melatonin receptor 2), in colostrum and assess the differentiation and polarization of the colostrum macrophages modulated by melatonin in the presence of breast tumor cells. Colostrum samples were collected from 116 mothers and tested for their melatonin and receptor levels. The colostrum cells were treated with or without melatonin and then cultured for 24 h in the presence or absence of breast tumor cells. The results showed that melatonin treatment increased the expression of MT1 and MT2 in the colostrum cells. Furthermore, melatonin treatment increased the percentage of M1 macrophages and decreased the percentage of M2 macrophages. When the colostrum macrophages were cocultured with breast tumor cells, melatonin reduced the percentage of both macrophage phenotypes and the cytokines tumor necrosis factor-alpha (TNF-α) and interleukin 8 (IL-8). These data suggest that melatonin can regulate the inflammatory process via M1 macrophages in the tumor microenvironment and, simultaneously, the progression of M2 macrophages that favor tumorigenesis.

show abstract

Section: Discussionsupporting

confidence: 87%

Polarization of Melatonin-Modulated Colostrum Macrophages in the Presence of Breast Tumor Cell Lines

Silva

França

Queiroz

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Breast cancer is the most common type of carcinoma in females, being the most prominent cause of cancer-related mortality in women worldwide [94,106,116,117]. The first treatment option for breast cancer is the combination between chemotherapeutic agents, radiation therapy, and surgical intervention.…”

Section: Malignant Diseasesmentioning

confidence: 99%

Photodynamic Therapy—An Up-to-Date Review

2021

View full text Add to dashboard Cite

The healing power of light has attracted interest for thousands of years. Scientific discoveries and technological advancements in the field have eventually led to the emergence of photodynamic therapy, which soon became a promising approach in treating a broad range of diseases. Based on the interaction between light, molecular oxygen, and various photosensitizers, photodynamic therapy represents a non-invasive, non-toxic, repeatable procedure for tumor treatment, wound healing, and pathogens inactivation. However, classic photosensitizing compounds impose limitations on their clinical applications. Aiming to overcome these drawbacks, nanotechnology came as a solution for improving targeting efficiency, release control, and solubility of traditional photosensitizers. This paper proposes a comprehensive path, starting with the photodynamic therapy mechanism, evolution over the years, integration of nanotechnology, and ending with a detailed review of the most important applications of this therapeutic approach.

show abstract

“…To avoid using small systemic dose or large local dose of plain chemotherapeutics, nanocarrier systems with controlled drug release can be employed. Particularly, bonetargeted drug delivery systems aim to concentrate drugs in tumor sites, protect drugs from rapid clearance, prolong their circulation times, enhance therapeutic efficacy, and reduce the systemic adverse effects [9,15,88,89].…”

Section: Drug Deliverymentioning

confidence: 99%

Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review

Bădilă

Rădulescu

Niculescu

et al. 2021

Cancers

View full text Add to dashboard Cite

In the last decades, the treatment of primary and secondary bone tumors has faced a slow-down in its development, being mainly based on chemotherapy, radiotherapy, and surgical interventions. However, these conventional therapeutic strategies present a series of disadvantages (e.g., multidrug resistance, tumor recurrence, severe side effects, formation of large bone defects), which limit their application and efficacy. In recent years, these procedures were combined with several adjuvant therapies, with different degrees of success. To overcome the drawbacks of current therapies and improve treatment outcomes, other strategies started being investigated, like carrier-mediated drug delivery, bone substitutes for repairing bone defects, and multifunctional scaffolds with bone tissue regeneration and antitumor properties. Thus, this paper aims to present the types of bone tumors and their current treatment approaches, further focusing on the recent advances in new therapeutic alternatives.

show abstract

Nanodoses of melatonin induces apoptosis on human breast cancer cells co-cultured with colostrum cells

Cited by 13 publications

References 42 publications

Polarization of Melatonin-Modulated Colostrum Macrophages in the Presence of Breast Tumor Cell Lines

Polarization of Melatonin-Modulated Colostrum Macrophages in the Presence of Breast Tumor Cell Lines

Photodynamic Therapy—An Up-to-Date Review

Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review

Contact Info

Product

Resources

About